Pressure Biosciences (PBIO) 0.2499 $PBIO
New Scientific Publication Suggests Pressure BioSciences' PCT Platform Could Play Significant Role in Personalized/Precision Medicine
PR Newswire - Tue Sep 01, 8:13AM CDT
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and the "Company"
, a leader in the development and sale of broadly enabling, pressure cycling technology ("PCT"-based sample preparation solutions to the worldwide life sciences industry, today announced the publication of an article with findings that suggest the Company's PCT Platform could play a significant role in expanding the reach of personalized/precision medicine. This role is based on PCT's unique ability to help reveal and analyze thousands of proteins in small diagnostic samples, such as tissue biopsies extracted in tiny needles from cancer patients, compared to current methods that analyze only hundreds of proteins at best. This significant increase in analyzed proteins could result in a better understanding of the patient's cancer, disease progression, response to therapy, and treatment options.
Pressure BioSciences, Inc. Reports Second Quarter and Year-to-Date 2015 Financial Results and Provides Business Update
PR Newswire - Mon Aug 17, 8:18AM CDT
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company" today announced financial results for the three and six-month periods ended June 30, 2015, which included increases in all major revenue categories for the quarter and record total revenue for the half-year period. The Company also provided a business update, which included the sale last week of 1,000,000 shares of restricted common stock at a significant premium to market ($0.46/share) to one of the most recognized and respected portfolio/fund managers in Poland. In return, in lieu of cash, the Company received 601,500 shares of Everest Investments, a publicly-traded company on the Main Market of the Warsaw Stock Exchange.
Pressure BioSciences, Inc. to Discuss Second Quarter 2015 Financial Results and Provide Business Update
PR Newswire - Fri Aug 14, 8:00AM CDT
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and the "Company" today announced that the Company will host a teleconference to discuss its Second Quarter 2015 financial results and to provide a business update. Anyone interested may listen to the teleconference either by telephone (live) or through a replay by telephone or on the Company's website.
Recent Agreement with DM WDM and Quark Ventures Results in Successful Equity Transaction, Significant New Opportunities, and Future Open Market Support for New Client Pressure BioSciences
PR Newswire - Fri Aug 14, 8:00AM CDT
Dom Maklerski WDM ("WDM", Central and Eastern Europe's (CEE) leading small-cap investment bank, and Quark Ventures ("QV", one of CEE's leading venture funds, today announced that key progress has been made as a result of a cooperation agreement recently signed between the financial services companies and their new client, Massachusetts (USA)-based Pressure BioSciences, Inc. (OTCQB: PBIO). This progress includes:
SeeThruEquity Issues Update on Pressure BioSciences (OTCQB: PBIO) Highlighting Robust Growth in 2015 and Recent Above Market Equity Offering
ACCESSWIRE - Mon Aug 03, 8:00AM CDT
NEW YORK, NY / ACCESSWIRE / August 3, 2015 / SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies, today announced it has issued an update on Pressure BioSciences, Inc. (OTCQB: PBIO).
Pressure BioSciences (PBIO) Showing Significant Potential for Continued Growth
ACCESSWIRE - Thu Jul 30, 7:00AM CDT
PHOENIX, AZ / ACCESSWIRE / July 30, 2015 / Months ago Uptick looked at Pressure BioSciences (OTCQB: PBIO), following the release of a Zacks Small-Cap report from April on the company and the award of over a million dollars in grant funding. In going over subsequent news from the company, Q1 earnings, and additional Zacks reports, it is clear that Zacks target goal of $2.50 per share is appropriate, along with the estimation that PBIO shares are highly undervalued. Much of this interest in the company is based on the continued progress that PBIO has made over this time on the development and commercialization of their patented and enabling Pressure Cycling Technology (PCT) platform.
Pressure BioSciences Closes $2,180,000 Initial Tranche of a $5 Million Private Placement
PR Newswire - Thu Jul 23, 8:21AM CDT
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and the "Company", a leader in the development and sale of broadly enabling, pressure cycling technology ("PCT"-based sample preparation solutions to the worldwide life sciences industry, today announced that it has closed on gross proceeds of $2,180,000 from the initial tranche of a $5 million Private Placement (the "Offering". Of the amount invested, $1,520,000 was received in cash and $660,000 was from the conversion of principal and interest on outstanding promissory notes. One or more additional tranches in the Private Placement may close on or before August 7, 2015.
Pressure BioSciences' PCT Platform a Key Workflow Component in Study to Discover Potential Biomarkers and Underlying Pathways in the Emergence and Progression of COPD-Associated Lung Cancer
PR Newswire - Wed Jul 15, 8:23AM CDT
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and the "Company", a leader in the development and sale of broadly enabling, pressure cycling technology ("PCT"-based sample preparation solutions to the worldwide life sciences industry, today announced that data on the identification of multiple molecular pathways in COPD-associated lung cancer were presented at the recent American Society for Mass Spectrometry ("ASMS" annual conference. To maximize the number of protein expression differentials that could be revealed, PCT was the method of choice for cell lysis and membrane disruption, two critical sample preparation steps in the study. Lead author and study presenter was Dr. Brian Sandri of the University of Minnesota ("UMN". Co-authors included other scientists from UMN, as well as from the Mayo Clinic (Rochester, MN), the Karolinska Institutet (Solna, Sweden), and the Center for Mass Spectrometry and Proteomics (St. Paul, MN).
Suggested Workflow to Accelerate the Discovery of New Biomarkers for Early Diagnosis and Prediction of Complications in Diabetes Includes Pressure BioSciences' Novel PCT Platform
PR Newswire - Mon Jul 13, 8:35AM CDT
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and the "Company", a leader in the development and sale of broadly enabling, pressure cycling technology ("PCT"-based sample preparation solutions to the worldwide life sciences industry, today announced the publication of an article in the internationally recognized journal Biochimica et Biophysica Acta. In the article, the authors reviewed the current status of biomarker discovery in diabetes mellitus ("diabetes" and provided insights into the need for, limitations, and possible solutions for biomarker discovery and validation in the field of diabetes research. The authors were Dr. Shiying Shao of the Tongji Hospital, Huazhong University of Science and Technology (Wuhan, PR China) and Drs. Tiannan Guo and Ruedi Aebersold of the Institute of Molecular Systems Biology, ETH Zurich (Zurich, Switzerland).
PBIO: Two New Applications of PBIO's PCT Platform Will Enhance Revenue Potential - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 08, 9:40AM CDT
PCT Platform Enables Better Classification of Prostate Cancer Tissue Biopsy Samples
Pressure BioSciences' PCT Platform Results in a Promising New Method for Improved Extraction of DNA from Rape Kits and other Forensic Samples
PR Newswire - Tue Jul 07, 7:16AM CDT
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and the "Company", a leader in the development and sale of broadly enabling, pressure cycling technology ("PCT"-based sample preparation solutions to the worldwide life sciences industry, today announced the development of a two-step, PCT-enhanced method for the selective differential extraction of male or female DNA from mixtures of sperm and vaginal epithelial cells recovered from cotton swabs. The results of the study were recently published in Analytical and Bioanalytical Chemistry, a leading peer-reviewed scientific journal. The authors of the paper were Dr. Deepthi V. Nori and Dr. Bruce R. McCord of the Department of Chemistry, Florida International University ("FIU".
Better Classification of Prostate Cancer Tissue Biopsy Samples Enabled by Pressure BioSciences' PCT Platform
PR Newswire - Mon Jun 29, 8:32AM CDT
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and the "Company", a leader in the development and sale of broadly enabling, pressure cycling technology ("PCT"-based sample preparation solutions to the worldwide life sciences industry, today announced that Tiannan Guo, MD Ph.D. of the Institute of Molecular Systems Biology, ETH Zurich, presented data on an improved method for the proteomic profiling and classification of prostate cancer tissue biopsy samples at the recent annual conference of the American Society for Mass Spectrometry.
Pressure BioSciences Selected by NIH to Exhibit and Showcase its PCT Technology Platform in the High Profile Innovation Zone at the 2015 BIO International Convention
PR Newswire - Mon Jun 15, 10:57AM CDT
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company", a worldwide leader in the development and sale of high pressure-based sample preparation systems to the life sciences research market, today announced its selection by the National Human Genome Research Institute of the National Institutes of Health ("NIH" to showcase its pressure cycling technology ("PCT" platform at the 2015 BIO International Convention. NIH has partnered with BIO to provide select SBIR grantees with premier visibility at BIO through participation in the newly created Innovation Zone. Earlier this year, PBI announced they had been awarded an SBIR Phase II grant of over $1,000,000, payable over two years. BIO 2015 is being held June 15-18, 2015 in Philadelphia, PA.
Pressure BioSciences, Inc. to Present at the 3rd Global Life Sciences Conference in Warsaw Poland
PR Newswire - Thu Jun 11, 7:06AM CDT
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company", a worldwide leader in the development and sale of high pressure-based sample preparation systems to the life sciences research market, today announced it has been invited to present at the 3rd Global Life Sciences Conference in Warsaw, Poland. The Conference will take place on the trading floor of the Warsaw Stock Exchange on June 11, 2015. Mr. Richard T. Schumacher, President and CEO of PBI, will present a business overview during the Company Sessions at 7:40 am EDT.
Pressure BioSciences' (PBIO) CEO Richard Schumacher on Q1 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed May 20, 9:23PM CDT
Pressure BioSciences, Inc. Reports Record Quarterly Revenue for First Quarter 2015 and Provides Business Update
PR Newswire - Mon May 18, 12:04PM CDT
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company", a leader in the development and sale of broadly enabling sample preparation solutions using pressure cycling technology ("PCT"-based instruments and consumables to the worldwide life sciences industry,today announced financial results for the three-month period ended March 31, 2015 and provided a business update.
Pressure BioSciences Selected to Present at Cavendish Global Health Impact Forum
PR Newswire - Fri May 08, 7:15AM CDT
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company", a leader in the development and sale of broadly enabling sample preparation solutions using pressure cycling technology ("PCT"-based instruments and consumables to the worldwide life sciences industry, today announced it has been selected to present at the Cavendish Global Health Impact Forum taking place May 10th to May 14th in La Jolla, California. Mr. Richard T. Schumacher, Founder and CEO of PBI will present a corporate overview on Monday afternoon, May 11, 2015. Mr. Schumacher plans to present an update on several of PBI's key development programs, including PCT-based sample preparation methods for next generation DNA sequencing; improved extraction of chemical toxins and carcinogens from environmental samples; improved detection of DNA in forensic samples, including rape kits; and the advantages of the PCT platform in drug discovery and design, cancer detection, and in the analysis of microbial communities in soil.
Data from Recently Published Studies Provide Strong Support for Current and Future Applications of Pressure BioSciences' PCT Platform
PR Newswire - Mon May 04, 8:31AM CDT
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company", a leader in the development and sale of broadly enabling sample preparation solutions using pressure cycling technology ("PCT"-based instruments and consumables to the worldwide life sciences industry, today announced the publication of three important articles in scientific journals by key opinion leaders in proteomics and genomics. The Company believes the articles highlight the clear advantages its patented PCT platform offers research scientists working in the areas of drug discovery and design, cancer detection, and the analysis of microorganism populations in soil. The Company also believes that the data offer compelling reasons why its PCT-based instruments and consumables may soon become a "need-to-have" tool in these and other areas of the life sciences.
Novel Environmental Epidemiology Application for Pressure BioSciences' Barozyme HT48 High-throughput System Developed
PR Newswire - Thu Apr 30, 8:42AM CDT
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company", a leader in the development and sale of broadly enabling sample preparation solutions using pressure cycling technology ("PCT"-based instruments and consumables to the worldwide life sciences industry, today announced that Dr. William Funk, Assistant Professor in Preventive Medicine-Cancer Epidemiology and Prevention at the Northwestern University ("NU" Feinberg School of Medicine, and his postdoctoral fellow, Dr. Daniel Ladror, presented a novel application for the Company's new Barozyme HT48 high-throughput PCT-based System (the "HT48 System" in environmental epidemiology. The presentations were made at the 2015 Pittcon Conference & Expo (largest annual conference & exposition for laboratory science) and at NU's 11th Annual Lewis Landsberg Research Day.
Pressure BioSciences to Collaborate with Southern University at New Orleans on Improving and Extending the Use of PBI's PCT Platform for the Detection of DNA in Forensic Samples
PR Newswire - Tue Apr 14, 6:21AM CDT
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and the "Company" today announced it has entered into a Collaboration Agreement with Southern University at New Orleans (SUNO) to focus on improving and extending the applications of the Company's unique and patented pressure cycling technology (PCT) platform for the detection of DNA in forensic samples. The program will be under the direction of Dr. Pam Marshall, Interim Director, Forensic Science Program and Assistant Professor, Department of Natural Sciences at SUNO.
New Scientific Publication Suggests Pressure BioSciences' PCT Platform Could Play Significant Role in Personalized/Precision Medicine
PR Newswire - Tue Sep 01, 8:13AM CDT
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and the "Company"
, a leader in the development and sale of broadly enabling, pressure cycling technology ("PCT"-based sample preparation solutions to the worldwide life sciences industry, today announced the publication of an article with findings that suggest the Company's PCT Platform could play a significant role in expanding the reach of personalized/precision medicine. This role is based on PCT's unique ability to help reveal and analyze thousands of proteins in small diagnostic samples, such as tissue biopsies extracted in tiny needles from cancer patients, compared to current methods that analyze only hundreds of proteins at best. This significant increase in analyzed proteins could result in a better understanding of the patient's cancer, disease progression, response to therapy, and treatment options. Pressure BioSciences, Inc. Reports Second Quarter and Year-to-Date 2015 Financial Results and Provides Business Update
PR Newswire - Mon Aug 17, 8:18AM CDT
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"
today announced financial results for the three and six-month periods ended June 30, 2015, which included increases in all major revenue categories for the quarter and record total revenue for the half-year period. The Company also provided a business update, which included the sale last week of 1,000,000 shares of restricted common stock at a significant premium to market ($0.46/share) to one of the most recognized and respected portfolio/fund managers in Poland. In return, in lieu of cash, the Company received 601,500 shares of Everest Investments, a publicly-traded company on the Main Market of the Warsaw Stock Exchange. Pressure BioSciences, Inc. to Discuss Second Quarter 2015 Financial Results and Provide Business Update
PR Newswire - Fri Aug 14, 8:00AM CDT
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and the "Company"
today announced that the Company will host a teleconference to discuss its Second Quarter 2015 financial results and to provide a business update. Anyone interested may listen to the teleconference either by telephone (live) or through a replay by telephone or on the Company's website. Recent Agreement with DM WDM and Quark Ventures Results in Successful Equity Transaction, Significant New Opportunities, and Future Open Market Support for New Client Pressure BioSciences
PR Newswire - Fri Aug 14, 8:00AM CDT
Dom Maklerski WDM ("WDM"
, Central and Eastern Europe's (CEE) leading small-cap investment bank, and Quark Ventures ("QV", one of CEE's leading venture funds, today announced that key progress has been made as a result of a cooperation agreement recently signed between the financial services companies and their new client, Massachusetts (USA)-based Pressure BioSciences, Inc. (OTCQB: PBIO). This progress includes: SeeThruEquity Issues Update on Pressure BioSciences (OTCQB: PBIO) Highlighting Robust Growth in 2015 and Recent Above Market Equity Offering
ACCESSWIRE - Mon Aug 03, 8:00AM CDT
NEW YORK, NY / ACCESSWIRE / August 3, 2015 / SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies, today announced it has issued an update on Pressure BioSciences, Inc. (OTCQB: PBIO).
Pressure BioSciences (PBIO) Showing Significant Potential for Continued Growth
ACCESSWIRE - Thu Jul 30, 7:00AM CDT
PHOENIX, AZ / ACCESSWIRE / July 30, 2015 / Months ago Uptick looked at Pressure BioSciences (OTCQB: PBIO), following the release of a Zacks Small-Cap report from April on the company and the award of over a million dollars in grant funding. In going over subsequent news from the company, Q1 earnings, and additional Zacks reports, it is clear that Zacks target goal of $2.50 per share is appropriate, along with the estimation that PBIO shares are highly undervalued. Much of this interest in the company is based on the continued progress that PBIO has made over this time on the development and commercialization of their patented and enabling Pressure Cycling Technology (PCT) platform.
Pressure BioSciences Closes $2,180,000 Initial Tranche of a $5 Million Private Placement
PR Newswire - Thu Jul 23, 8:21AM CDT
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and the "Company"
, a leader in the development and sale of broadly enabling, pressure cycling technology ("PCT"-based sample preparation solutions to the worldwide life sciences industry, today announced that it has closed on gross proceeds of $2,180,000 from the initial tranche of a $5 million Private Placement (the "Offering". Of the amount invested, $1,520,000 was received in cash and $660,000 was from the conversion of principal and interest on outstanding promissory notes. One or more additional tranches in the Private Placement may close on or before August 7, 2015. Pressure BioSciences' PCT Platform a Key Workflow Component in Study to Discover Potential Biomarkers and Underlying Pathways in the Emergence and Progression of COPD-Associated Lung Cancer
PR Newswire - Wed Jul 15, 8:23AM CDT
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and the "Company"
, a leader in the development and sale of broadly enabling, pressure cycling technology ("PCT"-based sample preparation solutions to the worldwide life sciences industry, today announced that data on the identification of multiple molecular pathways in COPD-associated lung cancer were presented at the recent American Society for Mass Spectrometry ("ASMS" annual conference. To maximize the number of protein expression differentials that could be revealed, PCT was the method of choice for cell lysis and membrane disruption, two critical sample preparation steps in the study. Lead author and study presenter was Dr. Brian Sandri of the University of Minnesota ("UMN". Co-authors included other scientists from UMN, as well as from the Mayo Clinic (Rochester, MN), the Karolinska Institutet (Solna, Sweden), and the Center for Mass Spectrometry and Proteomics (St. Paul, MN). Suggested Workflow to Accelerate the Discovery of New Biomarkers for Early Diagnosis and Prediction of Complications in Diabetes Includes Pressure BioSciences' Novel PCT Platform
PR Newswire - Mon Jul 13, 8:35AM CDT
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and the "Company"
, a leader in the development and sale of broadly enabling, pressure cycling technology ("PCT"-based sample preparation solutions to the worldwide life sciences industry, today announced the publication of an article in the internationally recognized journal Biochimica et Biophysica Acta. In the article, the authors reviewed the current status of biomarker discovery in diabetes mellitus ("diabetes" and provided insights into the need for, limitations, and possible solutions for biomarker discovery and validation in the field of diabetes research. The authors were Dr. Shiying Shao of the Tongji Hospital, Huazhong University of Science and Technology (Wuhan, PR China) and Drs. Tiannan Guo and Ruedi Aebersold of the Institute of Molecular Systems Biology, ETH Zurich (Zurich, Switzerland). PBIO: Two New Applications of PBIO's PCT Platform Will Enhance Revenue Potential - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 08, 9:40AM CDT
PCT Platform Enables Better Classification of Prostate Cancer Tissue Biopsy Samples
Pressure BioSciences' PCT Platform Results in a Promising New Method for Improved Extraction of DNA from Rape Kits and other Forensic Samples
PR Newswire - Tue Jul 07, 7:16AM CDT
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and the "Company"
, a leader in the development and sale of broadly enabling, pressure cycling technology ("PCT"-based sample preparation solutions to the worldwide life sciences industry, today announced the development of a two-step, PCT-enhanced method for the selective differential extraction of male or female DNA from mixtures of sperm and vaginal epithelial cells recovered from cotton swabs. The results of the study were recently published in Analytical and Bioanalytical Chemistry, a leading peer-reviewed scientific journal. The authors of the paper were Dr. Deepthi V. Nori and Dr. Bruce R. McCord of the Department of Chemistry, Florida International University ("FIU". Better Classification of Prostate Cancer Tissue Biopsy Samples Enabled by Pressure BioSciences' PCT Platform
PR Newswire - Mon Jun 29, 8:32AM CDT
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and the "Company"
, a leader in the development and sale of broadly enabling, pressure cycling technology ("PCT"-based sample preparation solutions to the worldwide life sciences industry, today announced that Tiannan Guo, MD Ph.D. of the Institute of Molecular Systems Biology, ETH Zurich, presented data on an improved method for the proteomic profiling and classification of prostate cancer tissue biopsy samples at the recent annual conference of the American Society for Mass Spectrometry. Pressure BioSciences Selected by NIH to Exhibit and Showcase its PCT Technology Platform in the High Profile Innovation Zone at the 2015 BIO International Convention
PR Newswire - Mon Jun 15, 10:57AM CDT
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"
, a worldwide leader in the development and sale of high pressure-based sample preparation systems to the life sciences research market, today announced its selection by the National Human Genome Research Institute of the National Institutes of Health ("NIH" to showcase its pressure cycling technology ("PCT" platform at the 2015 BIO International Convention. NIH has partnered with BIO to provide select SBIR grantees with premier visibility at BIO through participation in the newly created Innovation Zone. Earlier this year, PBI announced they had been awarded an SBIR Phase II grant of over $1,000,000, payable over two years. BIO 2015 is being held June 15-18, 2015 in Philadelphia, PA. Pressure BioSciences, Inc. to Present at the 3rd Global Life Sciences Conference in Warsaw Poland
PR Newswire - Thu Jun 11, 7:06AM CDT
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"
, a worldwide leader in the development and sale of high pressure-based sample preparation systems to the life sciences research market, today announced it has been invited to present at the 3rd Global Life Sciences Conference in Warsaw, Poland. The Conference will take place on the trading floor of the Warsaw Stock Exchange on June 11, 2015. Mr. Richard T. Schumacher, President and CEO of PBI, will present a business overview during the Company Sessions at 7:40 am EDT. Pressure BioSciences' (PBIO) CEO Richard Schumacher on Q1 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed May 20, 9:23PM CDT
Pressure BioSciences, Inc. Reports Record Quarterly Revenue for First Quarter 2015 and Provides Business Update
PR Newswire - Mon May 18, 12:04PM CDT
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"
, a leader in the development and sale of broadly enabling sample preparation solutions using pressure cycling technology ("PCT"-based instruments and consumables to the worldwide life sciences industry,today announced financial results for the three-month period ended March 31, 2015 and provided a business update. Pressure BioSciences Selected to Present at Cavendish Global Health Impact Forum
PR Newswire - Fri May 08, 7:15AM CDT
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"
, a leader in the development and sale of broadly enabling sample preparation solutions using pressure cycling technology ("PCT"-based instruments and consumables to the worldwide life sciences industry, today announced it has been selected to present at the Cavendish Global Health Impact Forum taking place May 10th to May 14th in La Jolla, California. Mr. Richard T. Schumacher, Founder and CEO of PBI will present a corporate overview on Monday afternoon, May 11, 2015. Mr. Schumacher plans to present an update on several of PBI's key development programs, including PCT-based sample preparation methods for next generation DNA sequencing; improved extraction of chemical toxins and carcinogens from environmental samples; improved detection of DNA in forensic samples, including rape kits; and the advantages of the PCT platform in drug discovery and design, cancer detection, and in the analysis of microbial communities in soil. Data from Recently Published Studies Provide Strong Support for Current and Future Applications of Pressure BioSciences' PCT Platform
PR Newswire - Mon May 04, 8:31AM CDT
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"
, a leader in the development and sale of broadly enabling sample preparation solutions using pressure cycling technology ("PCT"-based instruments and consumables to the worldwide life sciences industry, today announced the publication of three important articles in scientific journals by key opinion leaders in proteomics and genomics. The Company believes the articles highlight the clear advantages its patented PCT platform offers research scientists working in the areas of drug discovery and design, cancer detection, and the analysis of microorganism populations in soil. The Company also believes that the data offer compelling reasons why its PCT-based instruments and consumables may soon become a "need-to-have" tool in these and other areas of the life sciences. Novel Environmental Epidemiology Application for Pressure BioSciences' Barozyme HT48 High-throughput System Developed
PR Newswire - Thu Apr 30, 8:42AM CDT
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"
, a leader in the development and sale of broadly enabling sample preparation solutions using pressure cycling technology ("PCT"-based instruments and consumables to the worldwide life sciences industry, today announced that Dr. William Funk, Assistant Professor in Preventive Medicine-Cancer Epidemiology and Prevention at the Northwestern University ("NU" Feinberg School of Medicine, and his postdoctoral fellow, Dr. Daniel Ladror, presented a novel application for the Company's new Barozyme HT48 high-throughput PCT-based System (the "HT48 System" in environmental epidemiology. The presentations were made at the 2015 Pittcon Conference & Expo (largest annual conference & exposition for laboratory science) and at NU's 11th Annual Lewis Landsberg Research Day. Pressure BioSciences to Collaborate with Southern University at New Orleans on Improving and Extending the Use of PBI's PCT Platform for the Detection of DNA in Forensic Samples
PR Newswire - Tue Apr 14, 6:21AM CDT
Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and the "Company"
today announced it has entered into a Collaboration Agreement with Southern University at New Orleans (SUNO) to focus on improving and extending the applications of the Company's unique and patented pressure cycling technology (PCT) platform for the detection of DNA in forensic samples. The program will be under the direction of Dr. Pam Marshall, Interim Director, Forensic Science Program and Assistant Professor, Department of Natural Sciences at SUNO. 
